TMX September equities trading value rises to $439.66 billion
Bitget2026/10/06 13:04TMX Group released September 2026 trading statistics across its equities marketplaces, with volume at 13,749,465,011, up from 12,970,782,217 in August. Total equities value rose to $ 439.66 billion from $ 404.54 billion in August; transactions slipped to 28,968,353 from 29,041,028. Year-to-date equities value climbed 35.7% to $ 3.92 trillion; volume increased 17.4% to 138,902,595,089; transactions rose 29.7% to 291,826,827. TSX year-to-date value rose 38.1% to $ 3.72 trillion; volume increased 20.1% to 90,835,733,330; transactions gained 27.9% to 252,900,670. Montréal Exchange year-to-date derivatives volume increased 17.6% to 205,373,725 contracts; open interest rose 20.3% to 37,011,985. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TMX Group Limited published the original content used to generate this news brief via Newsfile (Ref. ID: 202610060900NEWSFILECNPR____20261006_317477_1) on October 06, 2026, and is solely responsible for the information contained therein.
- TMX Group released September 2026 trading statistics across its equities marketplaces, with volume at 13,749,465,011, up from 12,970,782,217 in August.
- Total equities value rose to $ 439.66 billion from $ 404.54 billion in August; transactions slipped to 28,968,353 from 29,041,028.
- Year-to-date equities value climbed 35.7% to $ 3.92 trillion; volume increased 17.4% to 138,902,595,089; transactions rose 29.7% to 291,826,827.
- TSX year-to-date value rose 38.1% to $ 3.72 trillion; volume increased 20.1% to 90,835,733,330; transactions gained 27.9% to 252,900,670.
- Montréal Exchange year-to-date derivatives volume increased 17.6% to 205,373,725 contracts; open interest rose 20.3% to 37,011,985.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
Crypto prices
More
